Dupilumab (Dupixent®)

Type: drug

Status: Investigational (for BP, approved for other atopic diseases)

Developer: Sanofi/Regeneron Pharmaceuticals

Breakthrough Summary

No summary available.

Mechanism of Action

Details pending.

Year: 2026